Novo Nordisk Annual Report 2021

Contents Introducing Novo Nordisk Strategic Aspirations Key risks Management Consolidated statements Additional information Novo Nordisk Annual Report 2021 52 Balance sheet at 31 December DKK million Assets Note 2021 2020 DKK million Note 2021 2020 Equity and liabilities Intangible assets 3.1 43,171 20,657 Share capital 4.2 462 470 Property, plant and equipment 3.1 55,362 50,269 Treasury shares 4.2 (6) (8) Investments in associated companies 525 582 Retained earnings 72,004 63,774 Deferred income tax assets 2.6 8,672 5,865 Other reserves 4.2 (1,714) (911) Other receivables and prepayments 267 674 Total equity 70,746 63,325 Other financial assets 916 1,066 Borrowings 4.5 12,961 2,897 Total non-current assets 108,913 79,113 Deferred income tax liabilities 2.6 5,271 2,502 Inventories 3.2 19,621 18,536 Retirement benefit obligations 1,280 1,399 Trade receivables 3.3 40,643 27,734 Other liabilities 3.5 360 Tax receivables 1,119 289 Provisions 3.4 4,374 4,526 Other receivables and prepayments 5,037 4,161 Total non-current liabilities 24,246 11,324 Marketable securities 4.3 6,765 Borrowings 4.5 13,684 7,459 Derivative financial instruments 4.4 1,690 2,332 Trade payables 8,870 5,717 Cash at bank 4.6 10,720 12,757 Tax payables 3,658 3,913 Total current assets Total assets 85,595 65,809 Other liabilities 3.5 19,600 17,005 194,508 144,922 Derivative financial instruments 4.4 2,184 1,365 Provisions 3.4 51,520 34,814 Total current liabilities 99,516 70,273 Total liabilities 123,762 81,597 Total equity and liabilities 194,508 144,922

View entire presentation